Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.jaut.2022.102959
DC Field | Value | |
---|---|---|
dc.title | Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING) | |
dc.contributor.author | Ma, Margaret | |
dc.contributor.author | Santosa, Amelia | |
dc.contributor.author | Kong, Kok Ooi | |
dc.contributor.author | Xu, Chuanhui | |
dc.contributor.author | Teng, Gim Gee | |
dc.contributor.author | Tang, Johnston GX | |
dc.contributor.author | Mak, Anselm | |
dc.contributor.author | Tay, Frank | |
dc.contributor.author | Ng, Victoria WW | |
dc.contributor.author | Koh, Joshua ZE | |
dc.contributor.author | Fong, Warren | |
dc.contributor.author | Chew, Li-Ching | |
dc.contributor.author | Low, Andrea | |
dc.contributor.author | Law, Annie | |
dc.contributor.author | Poh, Yih Jia | |
dc.contributor.author | Yeo, Siaw Ing | |
dc.contributor.author | Leung, Ying Ying | |
dc.contributor.author | Goh, Wei-Rui | |
dc.contributor.author | Roslan, Nur Emilia | |
dc.contributor.author | Chuah, Tyng Yu | |
dc.contributor.author | Angkodjojo, Stanley | |
dc.contributor.author | Arkachaisri, Thaschawee | |
dc.contributor.author | Teh, Kai Liang | |
dc.contributor.author | Phang, Kee Fong | |
dc.contributor.author | Sriranganathan, Melonie | |
dc.contributor.author | Tan, Teck Choon | |
dc.contributor.author | Cheung, Peter | |
dc.contributor.author | Lahiri, Manjari | |
dc.date.accessioned | 2023-10-27T06:45:39Z | |
dc.date.available | 2023-10-27T06:45:39Z | |
dc.date.issued | 2022-09 | |
dc.identifier.citation | Ma, Margaret, Santosa, Amelia, Kong, Kok Ooi, Xu, Chuanhui, Teng, Gim Gee, Tang, Johnston GX, Mak, Anselm, Tay, Frank, Ng, Victoria WW, Koh, Joshua ZE, Fong, Warren, Chew, Li-Ching, Low, Andrea, Law, Annie, Poh, Yih Jia, Yeo, Siaw Ing, Leung, Ying Ying, Goh, Wei-Rui, Roslan, Nur Emilia, Chuah, Tyng Yu, Angkodjojo, Stanley, Arkachaisri, Thaschawee, Teh, Kai Liang, Phang, Kee Fong, Sriranganathan, Melonie, Tan, Teck Choon, Cheung, Peter, Lahiri, Manjari (2022-09). Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING). ARTHRITIS & RHEUMATOLOGY 74 : 1577-1579. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jaut.2022.102959 | |
dc.identifier.issn | 2326-5191 | |
dc.identifier.issn | 2326-5205 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/245589 | |
dc.description.abstract | Background: Studies of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination are limited by small sample size, short follow up or at risk of selection bias. Methods: A national retrospective cohort study of consecutive AIIRD patients ≥12 years old, across 8 hospitals who received at least one dose of a COVID-19 mRNA vaccine. Patients were included from the date of 1st vaccine dose and censored at the time of flare or on the date of the clinic visit at least 3 months from cohort entry, whichever came first. Predictors of flare were determined by Cox proportional hazards analysis. Findings: 4627 patients (73% Chinese, 71% female) of median (IQR) age 61 (48, 70) years were included; 42% Rheumatoid arthritis, 14% Systemic lupus erythematosus and 11% Psoriatic arthritis. 47% were in remission, 41% low disease activity, 10% moderate disease activity and 1% in high disease activity. 18% patients flared, of which 11.7% were within the 3-month period of interest. 11.8% patients improved. Median (IQR) time-to-flare was 60 (30, 114) days. 25% flares were self-limiting, 61% mild-moderate and 14% severe. Older patients (53–65 years and >66 years) had a lower risk of flare [HR 0.6 (95% CI 0.5–0.8) and 0.7 (0.6–0.8) respectively]. Patients with inflammatory arthritis and with active disease had a higher risk of flare [HR 1.5 (1.2–2.0) and 1.4 (1.2–1.6), respectively]. Treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), immunosuppression and prednisolone was also associated with an increased risk of flare [HR 1.5 (1.1–2), 1.2 (1.1–1.4) and 1.5 (1.2–1.8) for prednisolone ≤7.5 mg respectively]. Interpretation: There was a moderately high rate of AIIRD flares after mRNA vaccination but also improvement in several patients. Severe flares and hospitalisation were rare. Thus, vaccination remains safe and highly recommended. | |
dc.language.iso | en | |
dc.publisher | WILEY | |
dc.source | Elements | |
dc.subject | Autoimmune inflammatory rheumatic diseases | |
dc.subject | COVID vaccines | |
dc.subject | Registry | |
dc.type | Article | |
dc.date.updated | 2023-10-26T03:04:57Z | |
dc.contributor.department | MEDICINE | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.1016/j.jaut.2022.102959 | |
dc.description.sourcetitle | ARTHRITIS & RHEUMATOLOGY | |
dc.description.volume | 74 | |
dc.description.page | 1577-1579 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
CONVINSING_JAutoimmunity.pdf | Published version | 1.33 MB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.